MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

NCT03502954 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-06-17

No results posted yet for this study

Summary

The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-039 after single and multiple doses in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

ABY-039

ABY-039

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Affibody

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-26
Primary Completion
2020-02-01
Completion
2020-03-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03502954 on ClinicalTrials.gov